AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05806567
Drug: P-gp victim drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Trial: NCT05806567
Drug: OATP1B1/BCRP victim drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT04736927
Drug: GLPG3667
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
Trial: NCT05135546
Drug: Recombinant nonimmunogenic staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®
Trial: NCT05135546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml of 0.9% solution of NaCl for inhalation
Trial: NCT05400070
Drug: Neoadjuvant therapy 1
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
Trial: NCT05550415
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Trial: NCT05550415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy
Trial: NCT06621069
Drug: Bisphosphonates
RxNorm normalized name: Bisphosphonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate Sodium or Zoledronic acid
Trial: NCT04569747
Drug: ADJUVANT ENDOCRINE THERAPY
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, daily per cycle
Trial: NCT06292858
Drug: IMB071703 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection
Trial: NCT05509725
Drug: Probiotic formulation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take 2 doses daily
Trial: NCT05509725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to take 2 doses daily
Trial: NCT05076149
Drug: VX-121/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT05076149
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT05076149
Drug: Placebo (matched to ELX/TEZ/IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Trial: NCT05076149
Drug: Placebo (matched to IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA for oral administration.
Trial: NCT05187520
Drug: Naldebain®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Trial: NCT06495463
Drug: Trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days.
Trial: NCT05719155
Drug: D759+D745+D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablet coadministration under fed condition
Trial: NCT05666128
Drug: HD-6277
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-6277 100mg
Trial: NCT05666128
Drug: HD-6277
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-6277 50mg
Trial: NCT05666128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05780294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
Trial: NCT04794205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug.
Trial: NCT06470633
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2 iv q3w
Trial: NCT00006066
Drug: Bacteriophage phi X 174
RxNorm normalized name: BACTERIOPHAGE PHI X174
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04819503
Drug: Spinal anaesthesia (sub-study 1)
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
Trial: NCT05428202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream containing base without active ingredients
Trial: NCT05156554
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
Trial: NCT05002998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as appropriate, per weight-based dosing volumes.
Trial: NCT06232785
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.8g intravenous injection 30min before the end of the operation
Trial: NCT06232785
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2ug/kg intravenous injection 30min before the end of the operation
Trial: NCT05610384
Drug: Ketorolac Injectable Solution
RxNorm normalized name: ketorolac Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
Trial: NCT05610384
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
Trial: NCT06439589
Drug: HRS2398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS2398: Tablets, 40mg/tablet, oral
Trial: NCT06202625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
Trial: NCT05117398
Drug: Standard antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
Trial: NCT05154123
Drug: Drug: AT-527 + rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.
Trial: NCT05154123
Drug: AT-527 + rosuvastatin
RxNorm normalized name: AT-527
DrugBank: AT-527 (DB16451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 1: A single dose of rosuvastatin will be administered.~* Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)
Trial: NCT05846399
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate 875-125mg by mouth twice daily for 5 days or Ciprofloxacin 500mg by mouth twice daily and clindamycin 450mg by mouth twice daily for 5 days
Trial: NCT05449535
Drug: JYB1904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Trial: NCT05449535
Drug: JYB1904 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
Trial: NCT05265091
Drug: KL590586 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
Trial: NCT06041425
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
Trial: NCT04573218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains glucose
Trial: NCT04147624
Drug: Souvenaid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
Trial: NCT05451615
Drug: Janus Kinase Inhibitor
RxNorm normalized name: Janus kinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
Trial: NCT04844905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
Trial: NCT04842006
Drug: Total neoadjuvant therapy (TNT)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
Trial: NCT06451328
Drug: Lignosus rhinoceros TM02®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignosus rhinoceros TM02®
Trial: NCT05904210
Drug: SEVENFACT®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulation Factor VIIa (Recombinant)
Trial: NCT06502067
Drug: Analgesia mangement group A,B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Trial: NCT04662528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1g capsules/day
Trial: NCT05311228
Drug: Azithromycin Powder
RxNorm normalized name: azithromycin Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromicyn intravena for 14 days
Trial: NCT06417177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo in pill form.
Trial: NCT02219373
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Trial: NCT06525636
Drug: KK8123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration
Trial: NCT06035861
Drug: XBD173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated with XBD173 90mg twice daily for 6 weeks
Trial: NCT05724628
Drug: Antibiotics (IV transitioned to oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin
Trial: NCT00416676
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05720026
Drug: SYSA1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
Trial: NCT05919095
Drug: Carrilizumab plus GEMOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment.
Trial: NCT06273111
Drug: 5% simvastatin ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% simvastatin ointment will be applied directly on IH lesion twice per day for 24 weeks
Trial: NCT04723563
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
Trial: NCT05046431
Drug: BAT2506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg/0.5mL
Trial: NCT05923411
Drug: Single dose of PF-07220060 as second Tablet Formulation
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
Trial: NCT05923411
Drug: Single dose of PF-07220060 as second Tablet Formulation
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
Trial: NCT05923411
Drug: Single dose of PF-07220060 as a Tablet Formulation
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07220060 as a tablet formulation administered under fed conditions
Trial: NCT05923411
Drug: Single dose of PF-07220060 as third tablet formulation
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
Trial: NCT06498089
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.
Trial: NCT04711356
Drug: Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein
Trial: NCT06619288
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
Trial: NCT06619288
Drug: TDF+3TC+EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
Trial: NCT06619288
Drug: DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
Trial: NCT05921305
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
Trial: NCT05069311
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery
Trial: NCT04588207
Drug: Urea
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day.
Trial: NCT05069311
Drug: Conventional intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
Trial: NCT05260385
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC1036 are administered orally QD or BID in 21-day cycles.
Trial: NCT05537558
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (AD) monotherapy or complex psychopharmacology such as two ADs or AD plus augmentation (second generation antipsychotics, mood stabilizers, lithium, FT3/FT4). Combination with diverse types of ongoing psychotherapy will be accepted, if commenced prior to baseline
Trial: NCT04005534
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Trial: NCT04005534
Drug: Preemptive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Trial: NCT06619678
Drug: MK-8507
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06249854
Drug: Bojungikki-tang(BJIKT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects
Trial: NCT06281353
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCA 90%
Trial: NCT01228110
Drug: Hydrocortison
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04981431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05479591
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.